All Stories

  1. Mucin 1 protects against severe Streptococcus pneumoniae infection
  2. At last, vaccine-induced protection against Helicobacter pylori
  3. Bioactivity in an Aggrecan 32-mer Fragment Is Mediated via Toll-like Receptor 2
  4. The MUC1 mucin protects against Helicobacter pylori pathogenesis in mice by regulation of the NLRP3 inflammasome
  5. Host Nonresponsiveness Does not Interfere With Vaccine-Mediated Protection Against GastricHelicobacterInfection
  6. ISCOMATRIX™ adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza
  7. Heat shock protein complex vaccination induces protection against Helicobacter pylori without exogenous adjuvant
  8. Vaccine‐Mediated Protection against Helicobacter pylori is not Associated with Increased Salivary Cytokine or Mucin Expression
  9. Why can’t we make an effective vaccine againstHelicobacter pylori?
  10. Helicobacter pylori thiolperoxidase as a protective antigen in single- and multi-component vaccines
  11. Mucosal vaccination: Lung versus nose
  12. DoHelicobacter pyloritherapeutic vaccines need to be tailored to the age of the recipient?
  13. Mouse Models of Helicobacter-Induced Gastric Cancer: Use of Cocarcinogens
  14. Helicobacter pylori defense against oxidative attack
  15. Long-Term Antibody and Immune Memory Response Induced by Pulmonary Delivery of the Influenza Iscomatrix Vaccine
  16. IncreasedHelicobacter feliscolonization in male 129/Sv mice fails to suppress gastritis
  17. Vaccinating Against Helicobacter pylori: Dissecting the Mechanism
  18. Mucin dynamics and enteric pathogens
  19. Did transmission of Helicobacter pylori from humans cause a disease outbreak in a colony of Stripe-faced Dunnarts (Sminthopsis macroura)?
  20. Evaluation of superoxide dismutase from Helicobacter pylori as a protective vaccine antigen
  21. Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX™ adjuvanted recombinant antigens
  22. Protease-Activated Receptor-1 Down-regulates the Murine Inflammatory and Humoral Response to Helicobacter pylori
  23. Targeting of whole killed bacteria to gastrointestinal M-cells induces humoral immunity in the female reproductive tract
  24. Helicobacter pylori in the 21st Century
  25. MUC1 Limits Helicobacter pylori Infection both by Steric Hindrance and by Acting as a Releasable Decoy
  26. A comparison of glycan expression and adhesion of mouse-adapted strains and clinical isolates of Helicobacter pylori
  27. M-Cell Targeting of Whole Killed Bacteria Induces Protective Immunity against Gastrointestinal Pathogens
  28. Erratum: Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing
  29. Systemic Immunization with Unadjuvanted Whole Helicobacter pylori Protects Mice Against Heterologous Challenge
  30. Muc1 Limits Helicobacter felis Binding to Gastric Epithelial Cells But Does not Limit Colonization and Gastric Pathology Following Infection
  31. Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing
  32. Mucosal immunology down under: Special Interest Group in Mucosal Immunology workshop, Australasian Society for Immunology, Sydney, Australia, 2 December 2007
  33. Evaluation of ISCOMATRIX™ and ISCOM™ vaccines for immunisation against Helicobacter pylori
  34. Biomedical applications of sheep models: from asthma to vaccines
  35. Immunogenicity and pathogenicity of Helicobacter infections of veterinary animals
  36. Muc1 Mucin Limits Both Helicobacter pylori Colonization of the Murine Gastric Mucosa and Associated Gastritis
  37. Helicobacter pylori flagella: antigenic profile and protective immunity
  38. Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background
  39. Considering Increased Mouse Stomach Mass When Calculating Prophylactic Vaccine Efficacy Against Helicobacter pylori
  40. Saponin-adjuvanted particulate vaccines for clinical use
  41. Local immune responses following nasal delivery of an adjuvanted influenza vaccine
  42. A sheep cannulation model for evaluation of nasal vaccine delivery
  43. Immunisation against Helicobacter felis infection protects against the development of gastric MALT Lymphoma
  44. Helicobacter pylori vaccines spiral into the new millennium
  45. Intranasal vaccination with ISCOMATRIX® adjuvanted influenza vaccine
  46. Post-immunisation gastritis and Helicobacter infection in the mouse: a long term study
  47. Helicobacter‐induced expression of Bcl‐XL in B lymphocytes in the mouse model: A possible step in the development of gastric mucosa‐associated lymphoid tissue (MALT) lymphoma
  48. Progress in vaccination against Helicobacter pylori
  49. Helicobacter pylori vaccines and mechanisms of effective immunity: Is mucus the key?
  50. Helicobacter pylori vaccines—the current status
  51. Dominant Nonresponsiveness to Helicobacter pylori Infection Is Associated with Production of Interleukin 10 but Not Gamma Interferon
  52. Further development of the Helicobacter pylori mouse vaccination model
  53. Helicobacter-induced expression of Bcl-xL in B lymphocytes in the mouse model — An important step in the development of gastric malt lymphoma
  54. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies
  55. A genetic basis for atrophy: dominant non-responsiveness and helicobacter induced gastritis in F1 hybrid mice
  56. Immunogenicity of recombinant BCG producing the GRA1 antigen from Toxoplasma gondii
  57. Suppression of helicobacter-associated inflammation in F1 hybrid mice; a genetic basis for atrophy
  58. Towards vaccination: what progress?
  59. Exacerbation of invasive aspergillosis by the immunosuppressive fungal metabolite, gliotoxin
  60. Evidence that gliotoxin enhances lymphocyte activation and induces apoptosis by effects on cyclic AMP levels
  61. INVESTIGATION OF THE POTENTIAL USE OF IMMUNOSUPPRESSIVE AGENT GLIOTOXIN IN ORGAN TRANSPLANTATION
  62. INVESTIGATION OF THE POTENTIAL USE OF IMMUNOSUPPRESSIVE AGENT GLIOTOXIN IN ORGAN TRANSPLANTATION
  63. Lack of correlation between proliferative and colony-forming assays and the true regenerative potential of transplanted bone marrow
  64. Rapid re‐expression of CD45RC on rat CD4 T cells in vitro correlates with a change in function
  65. Extragastric manifestations of Helicobacter pylori infection.
  66. Host genetic factors in susceptibility and resistance to Helicobacter pylori pathogenesis.